Showing 31-40 of 40 results for "".
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results previously reported from the phase 3 PRIME2 trial and will be submitted…
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers/2460816/Henry H.L. Chan, MD, PhD, FRCP, is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Chan is currently the Honorary Clinical Professor and Honorary Consultant Dermatologist of the Division of Dermatology, Department of Medicine, The University of Hong Kong, Quee…
- Sonrei Launches Three New Mineral Gel Sunscreenshttps://practicaldermatology.com/news/sonrei-launches-three-new-mineral-gel-sunscreens/2460756/Three new sunscreens are now available from Sonrei. The sunscreen collection now includes Sonrei Clearly Zinq Tinted Mineral Gel Sunscreen SPF 45, Sonrei Clearly Zinq Mineral Gel Sunscreen SPF 60 and Sonrei Kids Zinq Mineral Gel Sunscreen SPF 60, priced at $40 each. The Sonrei Mineral Gel formula…
- Study: Lipid that Aids Normal Skin Turnover May Help Psoriasishttps://practicaldermatology.com/news/study-lipid-that-aids-normal-skin-turnover-may-help-psoriasis/2457495/A lipid that helps keep skin cell turnover on track may help restore healthy turnover in psoriasis, investigators say. Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the …
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermatology,” w…
- AAD Awards 26 Shade Structure Grants to Protect America's Youthhttps://practicaldermatology.com/news/aad-awards-26-shade-structure-grants-to-protect-americas-youth/2457796/The American Academy of Dermatology (AAD) has awarded Shade Structure grants to 26 schools and nonprofit organizations across the country. The AAD awarded its 2018 AAD Shade Structure grants to the following organizations: Alabama Buhl Elementary School, Buhl, Sponsored by Kare…
- Second Skin Gets Second Chancehttps://practicaldermatology.com/news/second-skin-gets-second-chance/2458572/A “second skin” polymer may temporarily protect and tighten skin, and smooth wrinkles. Scientists at MIT, Massachusetts General Hospital, Living Proof, and Olivo Labs developed the material, which could also be used to deliver drugs to help treat skin conditions such as eczema and other types of d…
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011…
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-adjuvant-treatment-approach-for-stage-iii-braf-mutant-melanoma/15435/How can we choose the best adjuvant treatment strategy for melanoma patients with BRAF-activating tumors? Don’t miss this series.
- Previous
- Next